ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
17.32
-0.25
(-1.42%)
Closed November 19 4:00PM
17.50
0.18
( 1.04% )
Pre Market: 7:30AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

MED News

Official News Only

MED Discussion

View Posts
Slim6 Slim6 2 weeks ago
Very ugly quarterly results for Q3:
MED EPS is 95% below prior year's Q3.
👍️0
Zraced1 Zraced1 6 months ago
MED has Low Float of Shares 9.68M & High Short Interest 43.33%. It can Easily Surge
1st Break Out Support #
50-Day Moving Average $32.62
200-Day Moving Average $60.08
👍️0
spec machine spec machine 6 years ago
LOL, HOLY COW! Great buy, Still in?
👍️0
stocktrademan stocktrademan 7 years ago
MED buy 50.62









normal chart




log chart



👍️0
stocktrademan stocktrademan 10 years ago
$MED recent news/filings

bullish optionable

## source: finance.yahoo.com

Thu, 07 Aug 2014 22:14:08 GMT ~ NYSE stocks posting largest volume increases


read full: http://sg.finance.yahoo.com/news/nyse-stocks-posting-largest-volume-220412869--finance.html
*********************************************************

Thu, 07 Aug 2014 20:38:25 GMT ~ Medifast, Inc. Announces Second Quarter 2014 Financial Results

[at noodls] - Company Reports Second Quarter Earnings of $0.44 per Diluted Share OWINGS MILLS, Md., Aug. 7, 2014 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically ...

read full: http://www.noodls.com/view/2CABC9CD6A12F184E25736509FED4C49159CC421
*********************************************************

Thu, 07 Aug 2014 20:30:00 GMT ~ 4:30 pm Medifast beats by $0.04, misses on revs; guides Q3 EPS below consensus, revs below consensus; guides FY14 EPS in-line, revs below consensus


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#med
*********************************************************

Thu, 07 Aug 2014 20:10:40 GMT ~ MEDIFAST INC Files SEC form 8-K, Results of Operations and Financial Condition


read full: http://biz.yahoo.com/e/140807/med8-k.html
*********************************************************

Thu, 07 Aug 2014 20:05:00 GMT ~ Medifast, Inc. Announces Second Quarter 2014 Financial Results

[PR Newswire] - OWINGS MILLS, Md., Aug. 7, 2014 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven weight-loss products and programs, today reported financial ...

read full: http://finance.yahoo.com/news/medifast-inc-announces-second-quarter-200500084.html
*********************************************************


$MED charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$MED company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MED/company-info
Ticker: $MED
OTC Market Place: Not Available
CIK code: 0000910329
Company name: Medifast, Inc.
Company website: http://www.medifast.net
Incorporated In: DE, USA


$MED share structure

## source: otcmarkets.com

Market Value: $380,817,618 a/o Aug 07, 2014
Shares Outstanding: 13,131,642 a/o May 06, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$MED extra dd links

Company name: Medifast, Inc.
Company website: http://www.medifast.net

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MED/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MED/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MED+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MED+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MED+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MED/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MED/news - http://finance.yahoo.com/q/h?s=MED+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MED/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MED/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MED/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MED/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MED/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MED/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MED/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MED/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MED+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MED
DTCC (dtcc.com): http://search2.dtcc.com/?q=Medifast%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Medifast%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Medifast%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.medifast.net
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.medifast.net#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.medifast.net

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MED/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MED
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MED/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MED/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MED/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000910329&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MED/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MED/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MED/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MED/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MED&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MED
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MED/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MED+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MED+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MED
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MED
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MED+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MED/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MED+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MED.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MED
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MED/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MED/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MED/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MED/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MED
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MED
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MED:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MED
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MED



$MED DD Notes ~ http://www.ddnotesmaker.com/MED
👍️0
IPO$ IPO$ 11 years ago
WEIGHT LOSS STOCK
👍️0
investora2z investora2z 11 years ago
Though the analyst estimates for revenue were missed, the earnings were good and the company managed to report growth in revenues and net income both sequentially and on a yoy basis. The revenue increased 3.7% on a yoy basis from $93.57 million to $97.07 million. The net income increased 151% from $2.81 million in Q2'12 to $7.07 million in Q2'13. In Q1'13, the revenue was $96.04 million and the net income was $5.93 million. The revenue estimate for Q2'13 was in excess of $101 million. For the full year 2013, the average analyst estimate for EPS is $1.79. The revenue through Take Shape for Life, the company’s direct sales channel, increased 10 percent in the quarter to $61.4 million. The revenue guidance for 2013 given by the company is $375 million to $385 million, and EPS is expected to be in the range of $1.70 to $1.80. The company recently announced plans to pursue the strategic sale of its existing corporate Medifast Weight Control Centers and transition them to the franchise model over the next 12 to 18 months. This strategic transition is likely to make Medifast more financially flexible, and expand faster in the future. Some analysts consider Medifast as having good growth potential with decent valuations. The company is targeting $1 billion in revenue by 2017 which implies an annualized compounded growth of 23%. It plans to achieve this through gobal expansion, implementation of the "One Medifast" program and focus on acquiring talent and developing employee's capabilities. However, competition in the weight management market is fragmented with numerous approaches to deal with the problem. There are the direct competitors like Weight Watchers (WTW) and Herbalife (HLF). New vitamin supplements to counter this problem are being developed. Chromadex Corporation (CDXC) recently launched a vitamin derivative (nicotinamide riboside) to tackle the problem. Medifast is an established player and can be expected to grow with the market.
👍️0
investora2z investora2z 11 years ago
The upcoming earnings will be an important trigger for the stock. Analysts are estimating the company to report a revenue of around $101 million and EPS of 51 cents. For the full fiscal 2013, the revenues are expected to be $386 million and EPS is projected to be around $1.80. The company has surprised the street in the past, and hopefully, there will be some positive surprises in the earnings. A good set of numbers will help the stock to regain lost momentum. It has lost a bit of ground after a good rise recently. On the other hand, negative surprises will increase the weakness, and the correction may run deeper. The revenue growth has been very good over the years, and it is important that trend continues. The bottomline performance has not been that consistent. In Q1'13, there was modest growth in the revenues, and the net income jumped significantly by 49%. The recent correction has made the valuations better, and the stock is now trading around 21 times ttm earnings. The forward P/E of 12 indicates expectations of good growth in EPS over the next few quarters. The balance sheet is strong with very low debt (below $1 million) and around $69 million in cash (as on March 31). The net margins are a bit low at 5%, and that will be an important metric to watch in the earnings. The market for weight management is going to increase with time, and established players like Medifast are going to be benefited. The competition is also tough as there are numerous approaches to tackling obesity. Competitions comes from different segments, and big and small companies like Weight Watchers (WTW), NutriSystems (NTRI) and Herbalife (HLF) are getting aggressive. Chromadex Corporation (CDXC) has introduced a new vitamin derivative (NR) for obesity and diabetes management. Hopefully, Medifast will deliver a great set of numbers so that the stock resumes the uptrend.
👍️0
Penny Roger$ Penny Roger$ 13 years ago
~ Tuesday! $MED ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $MED ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=MED&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=MED&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=MED
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=MED#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=MED+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=MED
Finviz: http://finviz.com/quote.ashx?t=MED
~ BusyStock: http://busystock.com/i.php?s=MED&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=MED >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
RITCHEY RITCHEY 15 years ago
FEES: LIFE COACH?

Does Anyone know the FEEEs paid by a Life Coach?

Thank You for your time and consideration?

RITCHEY
👍️0
bbotcs bbotcs 15 years ago
MED: This stock is creeping up on a daily basis, on decent volume. Yesterday, I doubled down my position.
👍️0
kaith kaith 15 years ago
MED has a current Value of $24.84 per share. Therefore, it is undervalued compared to its Price of $14.25 per share.
MED has a Buy recommendation..

GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. MED has a forecasted Earnings Growth Rate of 28.00%, which VectorVest considers to be excellent.

EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. MED has a forecasted EPS of $0.66 per share.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. MED has a P/E of 21.59.
(from Vector Vest July 24, 2009)












































Sales: MED has annual sales of $113,000,000.00

Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. MED has a Sales Growth of 28.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.

Sales Per Share (SPS): MED has annual sales of $7.92 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.

Price to Sales Ratio (P/S): MED has a P/S of 1.80. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.

Shares: MED has 14,000,000.00 shares of stock outstanding.

Market Capitalization: MED has a Market Capitalization of $205,000,000.00. Market Capitalization is calculated by multiplying price times shares outstanding.

👍️0
XV19 XV19 16 years ago
I've been long gone from having a position..but I still use the products all the time...gp figure :)
👍️0
mlkrborn mlkrborn 16 years ago
$7s now.. should have stayed .. would have been my better investments. Oh well!
👍️0
mlkrborn mlkrborn 16 years ago
I got in and left with very tight stop loss order; minor loss. stabilized a bit after i left!
👍️0
XV19 XV19 16 years ago
been forever since I looked at MED stock. WTF?? under $5?? What happened?? Looks like they're still profitable? Did they dilute the hell out of themselves with splits??
👍️0
expat7 expat7 17 years ago
Medifast:

http://picture-funny.blogspot.com/2007/03/stupid-mirror.html
👍️0
mlkrborn mlkrborn 17 years ago
closed my position.
👍️0
mlkrborn mlkrborn 17 years ago
seems to be forming absolute resistance around 52 wks low level..
👍️0
mlkrborn mlkrborn 17 years ago
started inching up;
significant short interest..
could be a short squeeze bet or just a mid-term investment vehicle..
took a contrarian position..
DD
JMFHO
👍️0
mlkrborn mlkrborn 17 years ago

Took a position; 52 weeks low... Good marketing strategy and revised midyear upbeat profit and growth guestimates by the company...
👍️0
mlkrborn mlkrborn 17 years ago
Any idea as to entry?
tia
👍️0
MrSparex MrSparex 18 years ago
It's difficult to figure these stocks out. The only 2 stocks I ever had my finger on and could guess what they would do has been SLJB and AOOR....both of which I currently am clueless!
👍️0
expat7 expat7 18 years ago
Sure was. Keeping an eye one it for more.

Strange, such a good company with a good CEO, except for that bout of posting a handful of messages on Yahoo.



👍️0
MrSparex MrSparex 18 years ago
Good swing trade there eh!
👍️0
expat7 expat7 18 years ago
Closed out position @9.07 eom
👍️0
expat7 expat7 18 years ago
Locked in some profit here @8.23 eom
👍️0
expat7 expat7 18 years ago
2 Most Recently Initiated Coverage with Target @$16

01-19-2007 09:08:21 AM
1.) BB&T CAPITAL
TARGET: $16.00
BB&T CAPITAL initiates coverage on Medifast (AMEX: MED)
with a Buy rating and $16 price target.

Medifast is the leading easy-to-use, clinically proven meal replacement program. Medifast has been recommended by 15,000 physicians and used by over one million customers. Its programs have been proven effective through studies by researchers from major university teaching hospitals.
http://www.streetinsider.com/New+Coverage/BB&T+Capital+Starts+Medifast+(MED)+at+Buy/1509308.html

January 21, 2007 9:28:58 AM ET
2) eResearch
TARGET: 16.00
Medifast initiated with "buy"
January 21, 2007 9:28:58 AM ET
eResearch

NEW YORK, January 22 (newratings.com) - Analyst Laura Richardson of eResearch initiates coverage of Medifast Inc (MDF.ETR) with a "buy" rating. The 12-month target price is set to $16.

In a research note published on January 19, the analyst mentions that the company is well positioned to benefit going forward from weight-related concerns and is poised to capitalize on this trend through an increase in its ad spending. Medifast faces an opportunity to generate over $700 million in revenues in the forthcoming five-to-ten years, the analyst says. The company is expected to achieve 38% and 30% earnings growth this year and in the long-term, respectively, eResearch adds.
http://www.newratings.com/analyst_news/article_1460039.html
👍️0
expat7 expat7 18 years ago
First Indications for Today's Market Conditions are Positive Adding Further Support to MED Rebound imo:

1.) Stocks to swing with oil and Fed chief
Feb 10, 2007 8:33am ET145
http://today.reuters.com/news/articlenews.aspx?type=businessNews&storyid=2007-02-10T133253Z_01_N...

2.) Saudi minister says no more oil cuts needed: report
12:00 AM ET Feb 12, 2007
http://www.marketwatch.com/news/story/story.aspx?guid=%7B9671573D%2DB2AA%2D46C3%2DA2F4%2D0C63C43D09B...

3.)Oil Prices Fall to $58.45 a Barrel
Monday February 12, 6:48 am ET
http://biz.yahoo.com/ap/070212/oil_prices.html?.v=4

👍️0
expat7 expat7 18 years ago
Major Indexes and MED:

Note last Friday's sell-off on the dow, nasdaq and S&P 500:
http://finance.yahoo.com/q/bc?s=%5EDJI&t...
http://finance.yahoo.com/q/bc?s=%5eIXIC&...
http://finance.yahoo.com/q/bc?s=%5EGSPC&...

Now see the relation with MED. Is greater terms of % , but in pattern the relation is clear:
http://finance.yahoo.com/q/bc?s=MED&t=1d

Looking for an UP day today and if the indexes are positive, great acceleration for MED.
👍️0
expat7 expat7 18 years ago
Medifast #28 on Forbes 200 Best Small Companies

Forbes.com
'The 200 Best Small Companies'
#28 MEDIFAST
10.12.06, 6:00 PM ET
http://www.forbes.com/lists/2006/23/biz_...

Consecutive years on 200 Best 1
( 2005 rank NR )

Medifast ( MED ) makes weight management products.

Industry Specialty Stores

11445 Cronhill Drive
Owings Mills, MD 21117
phone: 410-581-8042
www.medifast.net
Ranking
5-Yr Avg ROE 29
Sales 182
Profits 190
Market Value 186
12-Mos Sales Growth 31
12-Mos EPS Growth 91
5-Yr Sales Growth 5
5-Yr EPS Growth 95

Board of Directors Rating 1 53



Growth
EPS 5-Yr Avg 25%
Last 12 Mos 37%
Sales 5-Yr 52%
Last 12 Mos 47%

Profitability
Return On Equity 5-Yr Avg 27%
Last 12 Mos 13%
Debt/Equity 5 13


2007 Estimates
EPS $0.55
PE 16

Market Data
Recent Price $8.68
Market Value 2 $115 mil
Enterprise Value 3 $127 mil
Enterprise Multiple 4 13

Income Statement
Latest 12 Mos Sales $60 mil
Latest 12 Mos Net Inc $5 mil
Operating Income 6 $9.8 mil

< Previous: Jos A Bank Clothiers Next: Multi-Fineline Electronix >

Rank | Company | State
Five-Year Avg. ROE | Sales | Profit | Market Value

👍️0
expat7 expat7 18 years ago
MED: Oversold and currently in place for upward correction imo.

Likely panic selling accelerated and capping with Friday's (Feb. 9) overall market pullback:

P/E
19.23 Medifast
27.03 Weight Watcher's International
22.76 NutriSystem
N/A Ediets.com

Good volume / low float combination.

MED O/S at 13.55 million. Float at 11.17 million.

Established history in industry 27 years. FDA approved.

3Q profit doubled with 79% revenue increase:

New products recently added with aggressive promotion.

Most recently initiated analyst rating, January 19, 2007, @buy with target price of $16.00.

http://www.sec.gov/cgi-bin/browse-edgar?company=Medifast+Inc&CIK=&filenum=&State=&SI....
http://finance.yahoo.com/q/ks?s=MED
http://finance.yahoo.com/q/ks?s=WTW
http://finance.yahoo.com/q/ks?s=NTRI
http://www.knobias.com/story.htm?eid=3.1.c600079773bf1f024a0d2c07906534d963abcc8bbb8a96168d0b2275a41....


👍️0
expat7 expat7 18 years ago
MED Chart:




👍️0
expat7 expat7 18 years ago
In @7.88 eom
👍️0
MrSparex MrSparex 18 years ago
Looking good...bottom fishers! I like it.
👍️0
XV19 XV19 18 years ago
November 24, 2006 - 1:29 PM EST

MED 13.33 0.28

Today 5d 1m 3m 1y 5y 10y



SYX 12.81 -0.70

Today 5d 1m 3m 1y 5y 10y



WMT 45.84 -0.26

Today 5d 1m 3m 1y 5y 10y



Schaeffer's Daily Market Blog Features: Intel, Wal-Mart Stores, Medifast, Systemax, and Family Dollar
Among the stocks featured in the November 24 edition of Schaeffer's Market Blog are Intel (NASDAQ:INTC), Wal-Mart Stores (NYSE:WMT), Medifast (NYSE:MED), Systemax (NYSE:SYX), and Family Dollar (NYSE:FDO). Schaeffer's Market Blog is just one of the many free market commentaries written every day at www.SchaeffersResearch.com - the home of Bernie Schaeffer and Schaeffer's Investment Research. The Market Blog is written throughout every trading day by Schaeffer's financial analysts and traders. They are quick insights to the day's most notable market activity from an options perspective. To have this report delivered to you free via email every day click on the following link and you'll also get an opportunity to win an iPod Nano. http://www.schaeffersresearch.com/redirect.aspx?CODE=PROB13M&PAGE=1 .

Don't forget that many of our observations are available as audio presentations that you can hear on your computer or download from Apple's iTunes Music Store to play on a portable device such as an iPod. To see the full menu of podcasts, please visit http://www.schaeffersresearch.com/commentary/podcasts/.

12:12 PM Medifast Short Sellers Getting Squeezed?

We could be seeing some short-covering activity on this day after Thanksgiving for weight and disease management products firm Medifast (NYSE:MED). Shares of the company have rallied nearly nine percent so far today, taking the stock above former resistance at the 11 level. According to Briefing.com, the investors are jumping on the equity due to a positive mention in a newsletter. Meanwhile, about 9.6 percent of the stock's float is sold short, and today's rally could be putting pressure on these bearish investors to buy back their positions. However, with today's light post-holiday volume, it will be interesting to see if MED holds today's gains into next week.

10:26 AM Intel Pulls Back on Restructuring News

Early yesterday morning, semiconductor bellwether Intel (NASDAQ:INTC) announced that it is reviewing the possibility of closing down or reducing the staff at its South Korean operations as part of its restructuring efforts. While it is a light trading day due to the Black Friday sales "holiday" in the States, INTC finds itself falling about one percent on news that normally boosts a company's shares. Technically, the stock is coming off a near-term top in the 22.50 area, a region that has troubled the security since late January. Furthermore, optimism is running high on the Street, with 18 of the 28 analysts covering the shares rating them a "buy" or better. Investors might want to keep an eye on short-term support in the 21.50 region, as a break of this level could indicate more downside potential over the short to intermediate term.

10:13 AM A Few Pesos More

Shares of Wal-Mart Stores (NYSE:WMT) have dipped about one percent this morning after The New York Times reported that the retailing giant received the permission from Mexico to open a bank in the country. Currently, WMT is pinned between its 10-day and 20-day moving averages, where it has spent the past seven trading sessions hovering above support at the 47.50 level. In sentiment, there mixed feelings toward the retailer on the Street, as eight of the 16 analysts covering the shares rate them a "hold," while the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.80 ranks above 84 percent of those taken during the past year. However, with WMT dropping some 8.6 percent since late October, this pessimism is to be expected.

9:53 AM Systemax Jumps on Earnings News

After the close on Wednesday, Systemax (NYSE:SYX) announced second-quarter earnings of $7.11 million, or 19 cents per share, compared to $1.52 million, or four cents per share, for the same period a year ago. Sales for the quarter rose eight percent to $547.2 million. The company also said it intends to release third-quarter results before the end of December. The security has gapped more than 14 percent higher this morning, jumping above former resistance at the 12.50 level. The equity is poised to finish the week back above its 10-week moving average as it bounces off the support of its ascending 20-week trendline.

9:45 AM Family Dollar Misses Extension Deadline

This morning, Family Dollar (NYSE:FDO) announced that it won't file its annual report by the Friday extended deadline, due to its continuing investigation into stock options. The board committee formed to investigate stock-option practices hasn't completed its work. At last check, the security was down more than one percent at $28.62 after being rejected yet again at the 29 level. This region is currently home to the stock's 10-week moving average, which has begun to roll over. This trendline could continue to hinder the equity's rally attempts during the near term. However, the shares have potential support at their 10-day and 20-day moving averages since the 28.30 region.

For more information on these stocks or any stock in your portfolio, feel free to visit our Schaeffer's Equity Scorecard feature. Click here to read all of today's Market Blog: http://www.schaeffersresearch.com/redirect.aspx?CODE=PROB13C&PAGE=1.

Take advantage of the timely Schaeffer commentaries by signing up for their free e-newsletters -- Opening View, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer's commentaries delivered to you free via email every day and get entered to win an IPod Nano. http://www.schaeffersresearch.com/redirect.aspx?CODE=PROB13M&PAGE=1.

About Schaeffer's Investment Research (www.SchaeffersResearch.com)

Schaeffer's Investment Research, founded by Bernie Schaeffer in 1981, is a financial information and trading resources company. It publishes Bernie Schaeffer's Option Advisor, the nation's leading options subscription newsletter. The firm's contrarian approach focuses on stocks with technical and fundamental trends that run counter to investor expectations. The firm's website, http://www.SchaeffersResearch.com , is recognized as one of the leading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron's. Click here for more details about Schaeffer's trading methodology: http://www.SchaeffersResearch.com/method .


Schaeffer's, Cincinnati
Joseph Hargett, 513-589-3800
releases@sir-inc.com



Source: Business Wire (November 24, 2006 - 1:29 PM EST)

News by QuoteMedia
www.quotemedia.com

👍️0
XV19 XV19 18 years ago
November 14, 2006 - 4:10 PM EST


Medifast Announces Record Third-Quarter and YTD Revenues and Profits

OWINGS MILLS, Md., Nov. 14 /PRNewswire-FirstCall/ --Medifast, Inc. (NYSE: MED) announced today third quarter results for the period ended September 30, 2006. For the quarter-ended September 30, 2006, Medifast reported revenue of $19.6 million, a 79% increase from $11 million in the third quarter of 2005.

The Company reported net income of $1,490,000, or $0.12 per basic share ($0.11 per diluted share), versus $607,000 or $0.05 per basic share ($0.05 per diluted share) in 2005. Net income in the third quarter of 2006 was positively impacted by a tax benefit received as a result of the Company's investment in infrastructure in prior years. The third quarter of 2006 represented the Company's 28th consecutive quarter of profitability.


For the nine months ended September 30, 2006, Medifast reported revenue of $58.8 million, an increase of 97% from $29.9 million for the nine months ended September 30, 2005. The Company reported net income of $4.6 million, or $.37 per basic share ($.34 per diluted share), versus $1.6 million or $.13 per basis share ($.13 per diluted share) in 2005.


The Company had stockholders' equity of $27.2 million and working capital of $13 million at September 30, 2006, compared to $21.3 million and $9.6 million at September 30, 2005, respectively.


'We are pleased with the third quarter results, which were driven by our growing customer base within a multi-channeled business. Our customer acquisition strategy is driving brand awareness, which benefits our direct to consumer business and also drives customers and business opportunity leads into our direct sales network while fueling significant walk-ins to our new medically supervised clinics, which are now operational in test markets. We believe that our diverse infrastructure model, which does not rely on a single distribution method, will allow Medifast to benefit long term in the over $40 billion weight loss category. In a customer driven world, Medifast is positioned to handle the needs of all types of customers. Whether a person is looking to lose weight utilizing the advice of a nutritionist, the support of a health coach, share their experience with others in an online community or stay under medical supervision in a clinic or doctor's office, Medifast provides a program to cater to the individual needs of the customer,' said Michael S. McDevitt, Medifast President and CFO.


'Medifast combines products and programs that have been clinically proven and trusted by physicians for over 25 years with a 21st century business model that recognizes that every consumer is an individual. Medifast is in the business of making people healthy in a time when we are experiencing an obesity epidemic in our country. Medifast is committed to providing a lasting solution for health and we are excited about expanding our programs to include broader recommendations for using Medifast for long term health as we move forward,' stated Bradley T. MacDonald, Chairman and CEO.


2006 Financial Guidance


The company expects to generate revenue of $70 to $72 million for the year with after-tax earnings of $0.38 to $0.40 per diluted share.


Third Quarter Conference Call


The Company will hold a conference call and webcast at 5:00 PM EST on November 14, 2006 to discuss second quarter results.


Interested participants should call (866) 700-6979 when calling within the United States or (617) 213-8836 when calling internationally. Please refer to pass code 61684562. There will be a playback available as well. To listen to the playback, please call (888) 286-8010 when calling within the United States or (617) 801-6888 when calling internationally. Please use pass code 85452066 for the replay. The replay will be available until February 21, 2007.


The webcast may be accessed via the Company's web site at http://www.medifastdiet.com. Interested parties should go to the section marked 'Investor Relations' to listen to the call. The webcast can be accessed until February 21, 2007.


Medifast has been helping people lose weight and achieve better health for 25 years. Its meal replacement foods have been proven effective in multiple clinical studies, recommended by over 15,000 physicians and used by more than 1 million customers. Medifast offers its customers world-class customer service and nutrition support.


This release contains forward-looking statements which may involve known, and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.


MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

September 30, 2006 December 31, 2005
(Unaudited) (Audited)
ASSETS
Current assets:
Cash $1,114,000 $1,484,000
Accounts receivable-net of
allowance for doubtful accounts
of $100,000 764,000 985,000
Income tax refund receivable 1,048,000 -
Inventory 8,003,000 5,475,000
Investment securities 2,420,000 2,700,000
Deferred compensation 640,000 525,000
Prepaid expenses and other
current assets 2,927,000 3,273,000
Note receivable - current 230,000 -
Deferred tax asset 90,000 -
Total Current Assets 17,236,000 14,442,000

Property, plant and equipment - net 11,578,000 9,535,000
Trademarks and intangibles - net 4,690,000 6,508,000
Deferred tax asset, net of current
portion 282,000 -
Note receivable, net of current
portion 1,305,000 -
Other assets 37,000 60,000

TOTAL ASSETS $35,128,000 $30,545,000

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued
expenses $2,661,000 $2,263,000
Income taxes payable 501,000 899,000
Line of credit 612,000 633,000
Current maturities of long-term debt 502,000 561,000
Deferred tax liability - current - 90,000
Total current liabilities 4,276,000 4,446,000

Long-term debt, net of current
portion 3,603,000 3,977,000
Deferred tax liability - non-current - 101,000
Total Liabilities 7,879,000 8,524,000

Stockholders' Equity:

Common stock; par value $.001 per
share; 20,000,000 authorized;
13,544,481 and 12,782,791 shares
issued and outstanding, respectively 14,000 13,000
Additional paid-in capital 26,326,000 21,759,000
Accumulated other comprehensive income 208,000 282,000
Retained Earnings 5,787,000 1,149,000
32,335,000 23,203,000

Less: cost of 240,749 and 210,902
shares of common stock in treasury (1,565,000) (1,075,000)
Less: unearned compensation (3,521,000) (107,000)
Total Stockholders' Equity 27,249,000 22,021,000

TOTAL LIABILITIES & STOCKHOLDERS'
EQUITY $35,128,000 $30,545,000




MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

Nine Months Ended Three Months Ended
September 30, September 30,
2006 2005 2006 2005
(Unaudited) (Unaudited) (Unaudited) (Unaudited)

Revenue $58,779,000 $29,865,000 $19,642,000 $10,985,000
Cost of sales 14,334,000 7,370,000 4,705,000 2,675,000
Gross Profit 44,445,000 22,495,000 14,937,000 8,310,000

Selling, general, and
administration 36,880,000 19,163,000 12,967,000 7,044,000

Income from operations 7,565,000 3,332,000 1,970,000 1,266,000

Other income/(expense)
Interest expense (271,000) ( 97,000) (90,000) (47,000)
Loss on sale of
Consumer Choice
Systems (323,000) - - -
Stock compensation
expense (346,000) - (164,000) -
Interest income 137,000 - 48,000 -
Other income (expense) 184,000 10,000 24,000 7,000

Income before provision
for income taxes 6,946,000 3,245,000 1,788,000 1,226,000
Provision for income
tax (expense) (2,307,000) (1,367,000) (298,000) (609,000)

Net income 4,639,000 1,878,000 1,490,000 617,000

Less: Preferred stock
dividend requirement - (291,000) - (10,000)

Net income $4,639,000 $1,587,000 $1,490,000 $607,000


Basic earnings per
share $0.37 $0.13 $0.12 $0.05
Diluted earnings per
share $0.34 $0.13 $0.11 $0.05

Weighted average
shares outstanding -
Basic 12,657,842 12,235,475 12,767,629 12,595,175
Diluted 13,493,421 12,438,531 13,603,208 12,989,147


SOURCE Medifast, Inc.



Source: PR Newswire (November 14, 2006 - 4:10 PM EST)

News by QuoteMedia
www.quotemedia.com
👍️0
XV19 XV19 18 years ago
nice to see the price climbing back up a bit.
👍️0
XV19 XV19 18 years ago
I'd like to see it back at the $15-17 range.
👍️0
Goodfill Goodfill 18 years ago
Anyone see this on the 25th? Medifast initiated with "outperform"

Monday, September 25, 2006 7:42:39 AM ET
Ryan, Beck & Co

NEW YORK, September 25 (newratings.com) - Analyst Mark Rupe of Ryan Beck & Co initiates coverage of Medifast Inc (MDF.ETR) with an "outperform" rating. The target price is set to $11.

In a research note published this morning, the analyst mentions that the company is expected to be able to generate 20%-30% revenue and EPS growth per annum for the next several years. Growth in the near term is likely to be driven mostly by Medifast’s direct-to-consumer and network marketing channels, with an increase in media spend, the analyst says. The company is also expected to witness continued growth in its weight loss business, Ryan Beck & Co adds.
👍️0
Goodfill Goodfill 18 years ago
Medifast Elects Two New Members To Its Board of Directors
OWINGS MILLS, Md., Oct. 2 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced the addition of two new independent members to the Board of Directors of the Owings Mills, Md. based meal replacement company. Dennis M. McCarthy, Esq. and Charles P. Connolly, Jr. were elected at the Medifast, Inc. Board of Directors meeting October 2, 2006. The Board now consists of 9 directors, including the Chairman of the Board.

"The Board is extremely pleased to welcome its two newest directors," said Bradley T. MacDonald, chairman of the board. "The professionalism, ethics, and experiences that these two gentlemen bring to the Board will add invaluable insight and expertise that will elevate Medifast, Inc."

Medifast's Board of Directors, at its annual board retreat in early June decided to add an additional two board members with one able to become the company's "financial expert" as a member of the audit committee. The Board will now have nine members with six members classified as "Independent Directors" according to the rules of the New York Stock Exchange and SEC regulations.

Mr. McCarthy practiced law for 21 years as a civil litigator in tort and contract cases. He was the founding member and managing partner of a Columbus, Ohio based law firm. Additionally, he served active duty in the U.S. Marine Corps for 16 years and served 22 years in reserve service. Mr. McCarthy retired in 2005 in the grade of Lieutenant General, having been the first Marine Reservist to serve in that grade. Mr. McCarthy is currently the Chief Executive of the Reserve Officers Association, a congressionally chartered association to support the reserve and guard forces of the United States.

Mr. Connolly is currently a consultant focusing on bank relationships, debt refinancing, merger and acquisition strategy and executive compensation design. Mr. Connolly spent 29 years at First Union National Bank that merged with Wachovia Bank in 2001. He retired in 2001 as the President and CEO of First Union National Bank.

About Medifast, Inc.

Medifast has been helping people lose weight and achieve better health for 25 years. Its meal replacement foods have been proven effective in multiple clinical studies, recommended by over 15,000 physicians and used by more than 1 million customers. Medifast offers its customers world-class customer service and nutrition support through a variety of program options for its customers.

This release contains forward-looking statements, which may involve known, and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.


👍️0
MrSparex MrSparex 18 years ago
sure..that'd be good
👍️0
XV19 XV19 18 years ago
wanna post the cliff notes version of the last filing?
👍️0
MrSparex MrSparex 18 years ago
The chart looks like it's primed to start up but who knows.
I wouldn't buy it because of their income statements.
👍️0
XV19 XV19 18 years ago
LOLOLOL. Well..I'm no longer a shareholder (took my profits a long time ago), BUT, I'm an avid Medifast user. Lost 60 lbs on the stuff and I'm living testament to it's quality.

Gotta say tho..looking at the stock chart the past year is enough to give anyone a heart attack. UGH. I first bought in at around $4 a long time ago. WHY it dumped from its near $20 high is just weird to me..

then again..I haven't done my DD and read the filings.
👍️0
MrSparex MrSparex 18 years ago
Your welcome...
Glad your here but I do have some bad news for you...
...your now an official assistant on this board and I know nothing about Medifast so I guess you'll have to do all the work! LOL
👍️0
XV19 XV19 18 years ago
wow..can't believe there hasn't been a Medifast board on iHub before this. Thanks for starting one. I'm a big fan.
👍️0

Your Recent History

Delayed Upgrade Clock